19:09 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D on Oct. 25 to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase...
13:27 , Oct 25, 2018 |  BC Extra  |  Financial News

Milestone raises $80M to fund pivotal trial of at-home tachycardia therapy

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $80 million in a series D to support a Phase III trial of its self-administered acute paroxysmal supraventricular tachycardia (PSVT) treatment, etripamil. Milestone began a Phase III study of...
22:16 , Aug 4, 2017 |  BioCentury  |  Finance

Milestone's options

Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series C round, which will give the cardiovascular company leeway to expand its core program or in-license a second cardio...
16:45 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Milestone closes first tranche of $55M series C

On Aug. 1, Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised an undisclosed amount in the first tranche of a $55 million series C round led by new investor Novo Holdings A/S (Hellerup, Denmark). New investors Forbion...
22:01 , Aug 1, 2017 |  BC Extra  |  Financial News

Milestone raises $55M in series C

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $55 million in a series C round led by Novo Holdings A/S (Hellerup, Denmark). New investors Forbion Capital Partners and Tekla Capital Management also participated, as did existing investors...
22:18 , Jun 23, 2017 |  BioCentury  |  Finance

Synthetic vitality

Versant Ventures and MPM Capital backed Repare Therapeutics Inc. with 2017’s largest series A round to get the synthetic lethality play to clinical proof of concept and possibly an exit. Repare emerged from stealth mode...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Repare launches with $68M series A

On June 22, cancer company Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds...
11:45 , Jun 22, 2017 |  BC Extra  |  Financial News

Repare launches with $68M

Repare Therapeutics Inc. (Montreal, Quebec) launched with a $68 million series A round. Versant Ventures , which founded the company, co-led the round with MPM Capital. Also participating were Fonds de solidarité FTQ, the Celgene...
11:03 , Jun 22, 2017 |  BC Innovations  |  Emerging Company Profile

Repare in progress

With a $68 million series A co-led by Versant Ventures and MPM Capital, Repare Therapeutics Inc. emerged from 18 months of stealth today, making a splash in the growing pool of newcos targeting cancer via...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Financial News

ScarX completes venture financing

ScarX Therapeutics Inc. , Toronto, Ontario   Business: Dermatology   Date completed: 2016-02-16   Type: Venture financing   Raised: C$2 million ($1.4 million)   Investors: Accel-Rx Health Sciences Accelerator; BDC Capital; MaRS Innovation ; and...